Extreme Value Stocks can be part of the investing equation, however; EVS, as rear view looking" mechanism, is an "extreme loser" in catching huge breakout growth winners at the right time.
During the 4th qtr. alone, AGN acquired SkinMedica, obtained FDA approval for Botox to treat OAB and recently bought MAP Pharm.
Don't you agree that because of these HUGE changes, AGN is a significantly different, and more valuable stock and company; that is yet to be factored into EVS's equation, and that these changes wont show up on EVS's radar, arguably, for another 12 to 18 months?
Dude, no wonder you've missed this latest AGN breakout move! You need a forward looking mechanism to supplement your EVS, static and rear-view device.